Last reviewed: May 12, 2026
Last updated: May 12, 2026
Written by:
Jay Hastings
,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on GLP-1 therapies, weight management protocols, and the genetic variables that shape every metabolic decision. Browse all Peptides & GLP-1 education
This is an independent editorial review. PlexusDx has no commercial relationship with Direct Meds or its parent company. No affiliate links or compensation are involved.
This review walks through how the Direct Meds GLP-1 program is structured end to end — evaluation, prescription, dispensing, and follow-up — so you can see how a compounded telehealth model actually operates. It is fair-balance editorial context, not a buying recommendation. As of April 2026.
Start your GLP-1 program with PlexusDx
One all-inclusive price covers your online provider visit, prescription, compounded medication, and shipping — no membership, no hidden fees. Complete a short intake and a licensed provider takes it from there.
Start your intake →
The GLP-1 program at a glance
Direct Meds combines a telehealth service with a compounded pharmacy. The core offering is remote clinical care: a licensed provider evaluates you virtually, writes a prescription, and the medication is dispensed either by a retail pharmacy for FDA-approved brand products or by a 503A compounding pharmacy for compounded semaglutide or tirzepatide. Program structure and current pricing appear on Direct Meds’s official website (search for the current URL at the time of reading).
From intake to prescription
The evaluation path mirrors most GLP-1 telehealth programs and moves in four steps. First, you complete an intake form documenting weight, medical history, and current medications. Second, a licensed clinician reviews it and, if you meet eligibility criteria, issues a prescription. Third, that prescription routes to a retail or licensed compounding pharmacy for fulfillment. Fourth, ongoing telehealth follow-up supports dose titration and side-effect management. Programs differ in provider type (physician versus NP or PA), pharmacy partner, and subscription design.
Which GLP-1 medications the model can involve
The pharmacology comes down to the underlying compound class. GLP-1 receptor agonists include semaglutide, liraglutide, and dulaglutide; GIP/GLP-1 dual agonists include tirzepatide. A program may dispense an FDA-approved brand product or a compounded alternative depending on its pharmacy pathway. Which specific molecule you receive, and in what form, is determined by the prescribing clinician and the program’s dispensing setup rather than by a menu you select from directly.
What the trials show
Key trial programs anchor the evidence: STEP evaluated semaglutide for weight management (The New England Journal of Medicine, 2021), SURMOUNT evaluated tirzepatide for weight management (NEJM 2022), and SURMOUNT-OSA evaluated tirzepatide for obstructive sleep apnea (NEJM 2024). Populations and endpoints vary across these programs, and outcomes differ from person to person.
Pricing snapshot
Direct Meds publishes pricing on its own website, and the monthly total varies by product, subscription tier, and whether the medication is branded or compounded. Across the telehealth GLP-1 market as of April 2026, monthly totals typically fall between roughly $200 and $700+, with wide variance. Confirm the live figure before committing.
The upstream genetics a GLP-1 program skips
What a GLP-1 program does not do is map the genetic architecture underneath your metabolic response. Variants in FTO (fat-mass and obesity-associated), GLP1R (the GLP-1 receptor gene and biological target of every GLP-1 compound), MC4R (a melanocortin receptor central to satiety and energy balance), and TCF7L2 (a transcription factor linked to glucose homeostasis and GLP-1 secretion) describe the baseline terrain any compound operates on. These are pathway-level markers; they do not predict response to a specific drug but they do frame the biology a clinician prescribes into.
PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols — available as Semaglutide Injection, Semaglutide Oral, Tirzepatide Injection, and Tirzepatide Oral. Before starting any GLP-1 pathway protocol, the Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights — including FTO, GLP1R, MC4R, and TCF7L2 markers that shape your GLP-1, appetite-regulation, and energy-balance biology. That upstream context is the test before you invest approach.
Not affiliated: PlexusDx is not affiliated with Direct Meds and has no commercial relationship with the companies reviewed in this article.
Related reading on PlexusDx: GLP 1 What Is, GLP 1 Receptor Agonist, GLP 1 Drugs, GLP 1 Hormone.
Disclaimer: This article is educational. PlexusDx is not affiliated with Direct Meds and has no commercial relationship with the companies reviewed. PlexusDx offers semaglutide and tirzepatide through its own Weight Management Protocols — this review compares approaches in the GLP-1 telehealth space. The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways — it does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.
Compare the PlexusDx approach: see the Weight Management Protocols — semaglutide and tirzepatide with the genetic context most telehealth programs don’t offer. Or start upstream: take the Precision Peptide Genetic Test to understand your GLP-1 pathway first.
Frequently Asked Questions
What GLP-1 medications does Direct Meds work with?
The model can involve GLP-1 receptor agonists such as semaglutide and GIP/GLP-1 dual agonists such as tirzepatide, dispensed as an FDA-approved brand or a compounded alternative. The specific medication depends on the clinician’s prescription and the program’s pharmacy pathway, confirmed on the brand’s own site.
How is eligibility decided?
A licensed clinician reviews your intake — weight, medical history, and current medications — and issues a prescription only if you meet the program’s criteria. Eligibility rules and any contraindications are set by the prescriber, not by the patient, and are documented on Direct Meds’s own website.
Does the genetic test predict which GLP-1 will work?
No. The Precision Peptide Genetic Test does not predict response to any specific compound or program. It analyzes pathway-level variants in FTO, GLP1R, MC4R, and TCF7L2 that describe baseline GLP-1 biology — context that applies whichever service prescribes a compound.
How does the PlexusDx GLP-1 approach differ?
PlexusDx pairs its semaglutide and tirzepatide protocols with the Precision Peptide Genetic Test, adding pathway-level genetic context that most telehealth-only programs do not offer alongside the medication itself. The aim is an informed conversation with your provider before you start, guided by your own baseline GLP-1 biology rather than a template protocol.
This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Direct Meds Weight Loss: Model, Eligibility, and Cost
Direct Meds Tirzepatide: Branded vs Compounded and Cost